Head-To-Head Analysis: Immunovant (NASDAQ:IMVT) versus Seer (NASDAQ:SEER)

Seer (NASDAQ:SEER) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Seer and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-484.51%	-25.88%	-23.07%
Immunovant	N/A	-81.55%	-73.09%

Institutional and Insider Ownership

75.2% of Seer shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Seer has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Seer and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1	0	0	0	1.00
Immunovant	1	3	6	1	2.64

Immunovant has a consensus price target of $30.78, indicating a potential upside of 17.56%. Given Immunovant’s stronger consensus rating and higher probable upside, analysts plainly believe Immunovant is more favorable than Seer.

Earnings & Valuation

This table compares Seer and Immunovant”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$14.17 million	7.68	-$86.60 million	($1.36)	-1.43
Immunovant	N/A	N/A	-$413.84 million	($2.84)	-9.22

Seer has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Summary

Seer beats Immunovant on 9 of the 14 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.